NanoHive is the developer of innovative, distinctive Hive 3D-printed spinal interbody fusion implant portfolio targeting multiple procedure approaches.
The NanoHive Medical investment opportunity:
The Company's Soft Titanium technology provides for load-bearing, energy-absorbing lattices that match bone mechanics for intraoperative fusion mass visualization
NanoHve Medical's design patents encompass core implant features targeting lattice appearance including nose & internal features, with patents in the US, Japan, Canada and the EU.
The company's investment opportunity consists of $5 million in convertible debt.
NanoHive Medical's revenues exceeded $3.5 million for 2023, and are projected to exceed $6 million for this year, and exceed $10 million for 2025. The Company is also projecting that it will be EBITDA positive in 2025.
6000 devices have been placed to date.
Outcome Capital is the Company's financial advisor and investment banker.
For more information regarding the opportunity, contact:
Patrick O'Donnell
President and CEO
NanoHive Medical
Tel 617 750 0383
Thomas Busby
Director
Outcome Capital
(978) 790-6347
________________________________________________________
What are your company's business or financial objectives?
Check out the services for growing life sciences companies provided by FC Global Strategies.
Our calendar link to schedule a call.
FC Global Strategies' Regional Directors:
Jeffrey Friedland, CEO - Based in the U.S.
(North America and Global)
+1 646 450 8909
Ross Swan - Based in Singapore
(Southeast Asia, Australia, Asia-Pacific)
+65 9181 9472
David Krutonog - Based in Israel
(Eastern Europe, Middle-East and North Africa
+972 50 974 3429
Claudio Hebling - Based in Brazil
(Latin America)
+55 19 99377 748
Vincent Paul Joseph - Based in India
(South Asia, India and Sri Lanka)
+91 962 620 9090
Olah Abiodun - Based in Nigeria
(Sub-Saharan Africa)
+234 812 029 8222
Commentaires